AU2002341356B2 - Compositions and methods for treatment of cancer - Google Patents

Compositions and methods for treatment of cancer Download PDF

Info

Publication number
AU2002341356B2
AU2002341356B2 AU2002341356A AU2002341356A AU2002341356B2 AU 2002341356 B2 AU2002341356 B2 AU 2002341356B2 AU 2002341356 A AU2002341356 A AU 2002341356A AU 2002341356 A AU2002341356 A AU 2002341356A AU 2002341356 B2 AU2002341356 B2 AU 2002341356B2
Authority
AU
Australia
Prior art keywords
ndv
glycoprotein
viral
strain
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002341356A
Other languages
English (en)
Other versions
AU2002341356A1 (en
Inventor
Charles Irving
Amos Panet
Zichria Zakay-Rones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravir Management LP
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
THERAVIR MAN LP
Theravir Management LP
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THERAVIR MAN LP, Theravir Management LP, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical THERAVIR MAN LP
Publication of AU2002341356A1 publication Critical patent/AU2002341356A1/en
Assigned to THERAVIR MANAGEMENT L.P., YISSUM RESEARCH DEVELOPMENT COMPANY reassignment THERAVIR MANAGEMENT L.P. Request for Assignment Assignors: OVCURE INC., YISSUM RESEARCH DEVELOPMENT COMPANY
Application granted granted Critical
Publication of AU2002341356B2 publication Critical patent/AU2002341356B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18161—Methods of inactivation or attenuation
    • C12N2760/18164—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002341356A 2001-09-12 2002-09-12 Compositions and methods for treatment of cancer Ceased AU2002341356B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL14539701A IL145397A0 (en) 2001-09-12 2001-09-12 Compositions and methods for treatment of cancer
IL145397 2001-09-12
PCT/IL2002/000765 WO2003022202A2 (en) 2001-09-12 2002-09-12 Compositions and methods for treatment of cancer

Publications (2)

Publication Number Publication Date
AU2002341356A1 AU2002341356A1 (en) 2003-06-19
AU2002341356B2 true AU2002341356B2 (en) 2007-11-15

Family

ID=11075779

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002341356A Ceased AU2002341356B2 (en) 2001-09-12 2002-09-12 Compositions and methods for treatment of cancer

Country Status (7)

Country Link
US (2) US7223389B2 (enExample)
EP (1) EP1424897A4 (enExample)
JP (1) JP2005508158A (enExample)
AU (1) AU2002341356B2 (enExample)
CA (1) CA2458543A1 (enExample)
IL (1) IL145397A0 (enExample)
WO (1) WO2003022202A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114774373A (zh) * 2022-04-27 2022-07-22 北京市农林科学院 信鸽新城疫病毒基因工程改造弱毒株及其制备方法和应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2819185A1 (fr) * 2001-01-08 2002-07-12 Oreal Composition cosmetique de texture pateuse a pulverulente et son utilisation en cosmetique
CN1946421B (zh) 2004-04-27 2013-07-17 威尔斯达特生物制剂公司 使用病毒和喜树碱进行的癌症治疗
NZ562951A (en) 2005-07-14 2011-09-30 Wellstat Biologics Corp Cancer treatment using a Newcastle disease virus, a fluoropyrimidine and a camptothecin combination
US20090175826A1 (en) * 2006-06-05 2009-07-09 Elankumaran Subbiah Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same
US20100297072A1 (en) * 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
ES2380289T3 (es) 2009-11-30 2012-05-10 United Cancer Research Institute Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer
CN102782475A (zh) * 2009-12-14 2012-11-14 新加坡科技研究局 检测器模块、检测器模块的控制方法以及检测系统
RU2482129C2 (ru) * 2010-11-11 2013-05-20 Никита Юрьевич Силко Штамм вируса болезни ньюкасла для создания на его основе кандидатного противоракового препарата и изучения механизмов онколизиса
WO2014011072A1 (ru) * 2012-07-11 2014-01-16 Zabelin Vladimir Arkad Evich Штамм-продуцент вируса болезни ньюкасла ndv/anas crecca/omsk/9/2010, используемый для создания на его основе кандидатного противоракового препарата
US10155991B2 (en) * 2013-08-15 2018-12-18 Xueliang James Xia Biomarkers for use in colorectal cancer
RU2562115C1 (ru) * 2014-11-13 2015-09-10 Федеральное государственное автономное образовательное учреждение высшего образования "Новосибирский национальный исследовательский государственный университет"(Новосибирский государственный университет, НГУ) Штамм вируса болезни ньюкасла для изучения онколитических свойств и механизмов онколизиса для создания прототипного противоопухолевого препарата
CN106868130B (zh) * 2014-12-24 2021-03-12 北京丽阳吉诺科技有限公司 用于结肠直肠癌中使用的生物标志物
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215745A (en) * 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5124148A (en) * 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5118502A (en) * 1989-06-20 1992-06-02 The University Of Georgia Research Foundation, Inc. Naturally attenuated newcastle disease vaccine and method of using the same
WO1992015672A1 (en) * 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
US5602023A (en) * 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
PT696326E (pt) 1993-04-30 2003-08-29 Wellstat Biologics Corp Utilizacao de ndv no fabrico de um medicamento para tratamento do cancro
EP0770397B1 (en) * 1995-10-18 2004-04-21 Akzo Nobel N.V. Newcastle disease virus combination vaccine
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
EP0974660A1 (en) * 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
IL157504A0 (en) * 2001-05-11 2004-03-28 Wellstat Biologics Corp Oncolytic virus therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Tzadok-David et al. J. Cancer Res. Clin. Oncol. 1995. Vol 121, pages 169-174. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114774373A (zh) * 2022-04-27 2022-07-22 北京市农林科学院 信鸽新城疫病毒基因工程改造弱毒株及其制备方法和应用

Also Published As

Publication number Publication date
EP1424897A2 (en) 2004-06-09
WO2003022202A3 (en) 2004-03-18
US7223389B2 (en) 2007-05-29
CA2458543A1 (en) 2003-03-20
US20100113335A1 (en) 2010-05-06
IL145397A0 (en) 2002-06-30
EP1424897A4 (en) 2009-06-17
WO2003022202A9 (en) 2004-04-22
JP2005508158A (ja) 2005-03-31
US20050031642A1 (en) 2005-02-10
WO2003022202A2 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
US20100113335A1 (en) Compositions and methods for treatement of cancer
US20210169956A1 (en) Increased activity of oncolytic newcastle disease virus
CN111944767A (zh) 以减毒的新城疫病毒为特征的组合物和用于治疗瘤形成的使用方法
AU2002341356A1 (en) Compositions and methods for treatment of cancer
JP2009529861A (ja) 鳥インフルエンザウイルスのｈ５ヘマグルチニンを発現する組み換えニューキャッスル病ウイルス
CN108546302A (zh) 一种复合多表位表达盒、其组成的重组病毒及应用
Ferreira et al. Protection conferred by commercial NDV live attenuated and double recombinant HVT vaccines against virulent California 2018 Newcastle disease virus (NDV) in chickens
JP2000253876A (ja) センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質
CN107106674A (zh) 口蹄疫疫苗
CN109321534A (zh) 一种重组基因viii型新城疫病毒弱毒株
CN107586759A (zh) 一种重组新城疫病毒的构建方法及应用
EP3316906A1 (en) Recombinant virus like particles using bovine immunodeficiency virus gag protein
KR101390554B1 (ko) 신규한 개 인플루엔자 바이러스(ｈ３ｎ２), 이를 포함하는 백신 조성물 및 ｈ３ｎ２ 바이러스 검정 키트
CN102559612B (zh) 表达尼帕脑炎病毒G蛋白的重组新城疫病毒LaSota疫苗株
CN102816741A (zh) 犬瘟热弱毒疫苗株f和h基因重组新城疫病毒活载体疫苗的构建及其应用
CA1152895A (en) Process for the preparation of novel influenza virus strains and influenza virus vaccines containing them
CN113736749B (zh) 一株禽流感病毒毒株及其应用
KR101908905B1 (ko) 인플루엔자 바이러스의 h9 및 h5의 다중 아형에 대한 교차 면역반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 백신
RU2701953C1 (ru) Способ получения поливалентной вакцины от гриппа
WO2020156693A1 (en) Recombinant oncolytic newcastle disease viruses with increased activity
PT1780216E (pt) Coronavírus canino pantrópico
JP2009268471A (ja) センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質
RU2706191C1 (ru) Поливалентная вакцина против гриппа
RU2680703C1 (ru) Кассета, предназначенная для получения плазмидных векторов, используемых для создания клеток-продуцентов вирусоподобных частиц (ВПЧ) вируса гриппа
RU2681482C1 (ru) MDCK клетка-продуцент белков вируса гриппа (варианты)

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY; THERAVIR MANA

Free format text: FORMER APPLICANT(S): YISSUM RESEARCH DEVELOPMENT COMPANY; OVCURE INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 12 MAR 2010 TO 12 APR 2010 IN WHICH TO PAY A RENEWAL FEE HASBEEN FILED .

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 12 APR 2010.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired